FDA Approves Intravenous Formulation of Secukinumab

This new route of administration is expected to become available during the fourth quarter of 2023.

Related Keywords

Philipj Mease ,Christy Siegel ,University Of Washington ,Novartis ,School Of Medicine ,Drug Administration ,Swedish Medical Center ,Psoriatic Arthritis ,Intravenous Iv ,Intravenous ,Tv ,Ankylosing Spondylitis ,Biologic Therapy ,Psoriasis ,Arthritis ,Oint Inflammation ,Interleukins ,Tnf Alpha ,Tumor Necrosis Factor Alpha ,Umor Necrosis Factor Tnf ,Achexin ,Achectin ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Ankylosing Spondylitis Bechterews Disease ,Children ,